- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04550663
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
September 20, 2020 updated by: Baorui Liu, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
One-center, Open-label, Single-arm Clinical Study of the Safety and Effectiveness of NKG2D CAR-T Cells Infusion in the Treatment of Relapsed/ Refractory NKG2DL+ Tumors
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
In this study,the enrollment of the patients must meet the inclusion and exclusion criteria .
All subjects will be asked to continue to undergo long-term gene safety follow-up.
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Baorui Liu, M.D
- Phone Number: 61331 +025-83106666 ext 61331
- Email: baoruiliu@nju.edu.cn
Study Contact Backup
- Name: Jie Shen, M.D
- Phone Number: 61331 +025-83106666
- Email: shenjie2008nju@163.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18, male & female;
- Patients with recurrent/refractory NKG2DL+ tumors diagnosis by pathological histology or cytology, focus on the inclusion of patients with hepatocellular carcinoma positive. (If recruit liver cancer patients, patients should with locally advanced or metastatic hepatocellular carcinoma (HCC), Barcelona clinic liver cancer (BCLC) staging system classification for B or C, for B, patients are not suitable for local treatment and/or surgery, or disease progression occurs after surgery and/or local treatment, or declined to surgery and/or local treatment);
- Patients who fail first-line treatment or are unwilling to receive first-line treatment;
- Disease progression occurred within 14 days before inclusion (RECIST criteria must be used as a basis for assessment of disease progression). According to RECIST V1.1, patients have at least one measurable lesion. Target lesions located within the field of previous therapeutic irradiation or within the area of local treatment (interventional or ablative treatment) are considered measurable if progress is confirmed;
The main organs function normally and meet the following requirements;
Blood routine examination shall be in accordance with (no blood transfusion within 14 days) :
- HB≥90g/L
- ANC ≥1.5×10^9/L
- PLT ≥75×10^9/L
serum biochemicals examination shall be in accordance with:
- BIL <1.5 upper normal limit (ULN)
- ALT and AST<2.5×ULN; In the case of liver metastasis, ALT and AST<5×ULN
- Serum Cr≤1×ULN, endogenous creatinine clearance≥50ml/min(Cockcroft-Gault formula);
- ECOG physical condition score: 0-1;
- Expected survival time ≥3 months;
- Cardiac function well before inclusion, no myocardial infarction attack occurred within half a year, and hypertension and other coronary heart disease were under control at present;
- No other uncontrollable benign diseases such as lung, kidney, liver infection before enrollment;
- Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days of enrollment and voluntarily use an appropriate method of contraception during observation and within 8 weeks after the last administration; men should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and within 8 weeks after the last administration;
- Patients voluntarily participated in this trial and sign the informed consent form;
- Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol;
- CAR-T cells amplify successfully to the expected number.
Exclusion Criteria:
- Pregnant or lactating women, pregnancy test positive by blood or urine within 48 hours before immune cell transplantation;
- Patients who need to be treated with systemic steroid;
Under following treatment conditions currently:
- during the other anti-tumor clinical observation period within 14 days before blood collection;
- patient has not recovered from acute side effects of the previous treatment;
- Receive radiotherapy within 4 weeks before enrollment;
- Patients who received any other cell therapy before;
- Transfection efficiency of lymphocytes of patients < 5% in feasibility assessment screening stage, or T cell amplification efficiency < 5 times;
- Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis;
- Patients with severe acute allergic reactions, or the attending doctor believes there is an unpredictable risk;
- Patients who have received other cell therapies;
- Other serious conditions that may limit patient's participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KD-025 CAR-T cells
NKG2D-based CAR-T cells infusion
|
Autologous genetically modified anti-NKG2DLs CAR transduced T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: 90 days post infusion
|
Incidence of dose-limiting toxicities
|
90 days post infusion
|
The occurrence of AEs and SAEs during the study treatment
Time Frame: 0 to 28 days post infusion
|
An adverse event is any undesirable experience associated with the use of a medical product in a patient
|
0 to 28 days post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective remission rate(ORR)
Time Frame: 1 year post infusion
|
Imaging assessment of tumor remission
|
1 year post infusion
|
Progression free survival(PFS)
Time Frame: 2 year post infusion
|
Progress Free Survival after administration
|
2 year post infusion
|
Overall survival (OS)
Time Frame: 2 years post infusion
|
overall survival refers to the period from being included in the test group to death caused by any reason
|
2 years post infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 25, 2020
Primary Completion (Anticipated)
September 25, 2022
Study Completion (Anticipated)
March 25, 2023
Study Registration Dates
First Submitted
September 8, 2020
First Submitted That Met QC Criteria
September 14, 2020
First Posted (Actual)
September 16, 2020
Study Record Updates
Last Update Posted (Actual)
September 23, 2020
Last Update Submitted That Met QC Criteria
September 20, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-172-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on KD-025 CAR-T cells
-
Jiujiang University Affiliated HospitalKAEDIWithdrawnGlioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon CancerChina
-
Yan'an Affiliated Hospital of Kunming Medical UniversityKAEDIUnknownB Cell Lymphoma | B-cell Acute Lymphoblastic LeukemiaChina
-
jianming xuKAEDIRecruiting
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom